Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex Pharma | Vienna | Healthcare | Biotechnology & Medical Research | €113.94B | -253.6x | 2.21 | €435.35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Regeneron Pharma | Vienna | Healthcare | Biotechnology & Medical Research | €100.75B | 25.2x | €921.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
IQVIA Holdings | Vienna | Healthcare | Biotechnology & Medical Research | €38.60B | 29.7x | 0.9 | €211.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
argenx SE | Vienna | Healthcare | Biotechnology & Medical Research | €29.52B | -157.7x | -3.02 | €479.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE DRC | Vienna | Healthcare | Biotechnology & Medical Research | €26.17B | -52.2x | 0.47 | €111 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Vienna | Healthcare | Biotechnology & Medical Research | €20.40B | -3.8x | 0.01 | €53.38 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab AS | Vienna | Healthcare | Biotechnology & Medical Research | €13.68B | 18.9x | 0.92 | €216.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Vienna | Healthcare | Biotechnology & Medical Research | €8.93B | 134.2x | -1.71 | €40.06 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos NV | Vienna | Healthcare | Biotechnology & Medical Research | €1.78B | 6.3x | 0.2 | €26.74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Vienna | Healthcare | Biotechnology & Medical Research | €947.69M | -5.6x | 0.09 | €5.64 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CureVac NV | Vienna | Healthcare | Biotechnology & Medical Research | €587.03M | -2.1x | -0.14 | €2.64 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Valneva | Vienna | Healthcare | Biotechnology & Medical Research | €414.14M | -10.8x | 0.04 | €2.58 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medigene | Vienna | Healthcare | Biotechnology & Medical Research | €27.24M | -1.5x | -0.04 | €1.89 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |